Jay Wu
VM Discovery, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jay Wu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:19 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07636785 · A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsVM Discovery, Inc. · recruiting · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Preclinical Development of Selective PKC_epsilon Inhibitors to Treat AlcoholismR44AA014843 · NIAAA · VM DISCOVERY, INC. · fiscal years 2007 to 2013 · $463,933 awarded in 2013Same name and institution; not confirmed by an ID
- TAS::75 0849::TAS DEVELOPMENT OF ANTI-CANCER AGENTS.26120100010 · NCI · VM DISCOVERY, INC. · fiscal years 2010 · $198,224 awarded in 2010Same name and institution; not confirmed by an ID
- Multi-Property Design Selective PKC_epsilon InhibitorsR43AA014843 · NIAAA · VM DISCOVERY, INC. · fiscal years 2004 · $98,153 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:19 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- 121 citationsRCR 12.6
- Detection of dysplasia at colonoscopy using laser-induced fluorescence: a blinded study.Gastrointest Endosc · 1996115 citationsRCR 4.5
- 112 citationsRCR 4.7
- Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.J Clin Oncol · 202092 citationsRCR 3.4
- Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.Clin Cancer Res · 201754 citationsRCR 1.6
- Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer.Clin Transl Gastroenterol · 201952 citationsRCR 1.8
- 45 citationsRCR 1.9
- Simethicone improves bowel cleansing with low-volume polyethylene glycol: a multicenter randomized trial.Endoscopy · 201843 citationsRCR 2.3
- Increased risk of advanced neoplasms among asymptomatic siblings of patients with colorectal cancer.Gastroenterology · 201340 citationsRCR 1.1
- Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer.Oncogene · 201531 citationsRCR 0.9